Abstract
The Polycomb Group protein EZH2 is upregulated in most prostate cancers, and its overexpression is associated with poor prognosis. Most insights into the functional role of EZH2 in prostate cancer have been gained using cell lines and EZH2 inactivation studies. However, the question remains whether overexpression of EZH2 can initiate prostate tumourigenesis or drive tumour progression. Appropriate transgenic mouse models that are required to answer such questions are lacking. We developed one such transgenic mouse model for conditional overexpression of Ezh2. In this transgene, Ezh2 and Luciferase are transcribed from a single open reading frame. The latter gene enables intravital bioluminescent imaging of tissues expressing this transgene, allowing the detection of tumour outgrowth and potential metastatic progression over time. Prostate-specific Ezh2 overexpression by crossbreeding with Probasin-Cre mice led to neoplastic prostate lesions at low incidence and with a long latency. Compounding a previously described Bmi1-transgene and Pten-deficiency prostate cancer mouse model with the Ezh2 transgene did not enhance tumour progression or drive metastasis formation. In conclusion, we here report the generation of a wildtype Ezh2 overexpression mouse model that allows for intravital surveillance of tissues with activated transgene. This model will be an invaluable tool for further unravelling the role of EZH2 in cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abbas A, Gupta S (2008) The role of histone deacetylases in prostate cancer. Epigenetics 3:300–309
Ammirante M et al (2013) An IKKα–E2F1–BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. Genes Dev 27:1435–1440. doi:10.1101/gad.220202.113
Barsotti AM et al (2015) Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth. Oncotarget 6:2928–2938. doi:10.18632/oncotarget.2758
Beguelin W et al (2013) EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23:677–692. doi:10.1016/j.ccr.2013.04.011
Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV (2006) Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 5:1886–1901
Berg T et al (2014) A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis. Blood 123:3914–3924. doi:10.1182/blood-2012-12-473439
Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K (2003) EZH2 is downstream of the pRB–E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22:5323–5335. doi:10.1093/emboj/cdg542
Butler LM et al (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60:5165–5170
Cao Q et al (2008) Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27:7274–7284. doi:10.1038/onc.2008.333
Chen H, Tu SW, Hsieh JT (2005) Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 280:22437–22444. doi:10.1074/jbc.M501379200
Chen MF, Chen WC, Chang YJ, Wu CF, Wu CT (2010) Role of DNA methyltransferase 1 in hormone-resistant prostate cancer. J Mol Med (Berl) 88:953–962. doi:10.1007/s00109-010-0640-3
Chng KR, Chang CW, Tan SK, Yang C, Hong SZ, Sng NY, Cheung E (2012) A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. EMBO J 31:2810–2823. doi:10.1038/emboj.2012.112
Ghoshal K et al (2004) Role of human ribosomal RNA (rRNA) promoter methylation and of methyl-CpG-binding protein MBD2 in the suppression of rRNA gene expression. J Biol Chem 279:6783–6793. doi:10.1074/jbc.M309393200
Glinsky GV, Berezovska O, Glinskii AB (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115:1503–1521. doi:10.1172/JCI23412
Herrera-Merchan A, Arranz L, Ligos JM, de Molina A, Dominguez O, Gonzalez S (2012) Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat Commun 3:623. doi:10.1038/ncomms1623
Hodis E et al (2012) A landscape of driver mutations in melanoma. Cell 150:251–263. doi:10.1016/j.cell.2012.06.024
Ittmann M et al (2013) Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res 73:2718–2736. doi:10.1158/0008-5472.CAN-12-4213
Koppens MA et al (2016) Deletion of polycomb repressive complex 2 from mouse intestine causes loss of stem cells. Gastroenterology. doi:10.1053/j.gastro.2016.06.020
Liao CP et al (2007) Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res 67:7525–7533. doi:10.1158/0008-5472.CAN-07-0668
Metzger E et al (2005) LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437:436–439. doi:10.1038/nature04020
Min J et al (2010) An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 16:286–294. doi:10.1038/nm.2100
Morin RD et al (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42:181–185. doi:10.1038/ng.518
Nacerddine K et al (2012) Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer. J Clin Invest 122:1920–1932. doi:10.1172/JCI57477
Perry AS, Watson RW, Lawler M, Hollywood D (2010) The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol 7:668–680. doi:10.1038/nrurol.2010.185
Schulz WA, Hatina J (2006) Epigenetics of prostate cancer: beyond DNA methylation. J Cell Mol Med 10:100–125
Serresi M et al (2016) Polycomb repressive complex 2 is a barrier to KRAS-driven inflammation and epithelial-mesenchymal transition in non-small-cell lung cancer. Cancer Cell 29:17–31. doi:10.1016/j.ccell.2015.12.006
Siddique HR et al (2013) BMI1 polycomb group protein acts as a master switch for growth and death of tumor cells: regulates TCF4-transcriptional factor-induced BCL2 signaling. PLoS ONE 8:e60664. doi:10.1371/journal.pone.0060664
Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM, Copeland RA (2010) Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci USA 107:20980–20985. doi:10.1073/pnas.1012525107
Varambally S et al (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624–629. doi:10.1038/nature01075
Westerman BA et al (2012) GFAP-Cre-mediated transgenic activation of Bmi1 results in pituitary tumors. PLoS ONE 7:e35943. doi:10.1371/journal.pone.0035943
Wissmann M et al (2007) Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol 9:347–353. doi:10.1038/ncb1546
Wu X et al (2001) Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 101:61–69
Xu K et al (2012) EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338:1465–1469. doi:10.1126/science.1227604
Yang YA, Yu J (2013) EZH2, an epigenetic driver of prostate cancer Protein. Cell 4:331–341. doi:10.1007/s13238-013-2093-2
Yap DB et al (2011) Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117:2451–2459. doi:10.1182/blood-2010-11-321208
Yegnasubramanian S et al (2004) Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64:1975–1986
Zhang H et al (2016) Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer. Cancer Discov. doi:10.1158/2159-8290.CD-16-0164
Zhao JC et al (2012) Cooperation between Polycomb and androgen receptor during oncogenic transformation. Genome Res 22:322–331. doi:10.1101/gr.131508.111
Acknowledgements
We thank Rahmen Bin Ali for implanting the transgenic blastocysts, the animal laboratory facility for maintenance of the mouse colony and the mouse pathology facility for producing immunohistochemical samples. We are grateful to ST Jacob for providing the pHrD-IRES-Luc plasmid. This work was supported by the Dutch Cancer Society (KWF).
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Koppens, M.A.J., Tanger, E., Nacerddine, K. et al. A new transgenic mouse model for conditional overexpression of the Polycomb Group protein EZH2. Transgenic Res 26, 187–196 (2017). https://doi.org/10.1007/s11248-016-9993-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11248-016-9993-x